introduction lung cancer deadliest cancer estimated 1.8 million death worldwide causing death breast prostate colorectal brain cancer combined although decreasing trend mortality rate observed mainly europe north america several high-income country world mortality rate still increasing globally strong geographical difference linked smoking pattern air quality overall five-year survival patient type although grouped stage survival varies early- late-stage owing mostly distant metastasis survival differs two main histological subtypes non-small cell nsclc dominating entity adenocarcinoma squamous cell carcinoma small cell lung cancer sclc overall five-year survival rate around respectively however difference reflect primarily rapidly developing nature sclc typically diagnosed distant metastasis stage survival linked stage need identify marker earlier diagnosis individualized treatment increase diagnostic prognostic precision several dna rna protein biomarker candidate identified mainly based tissue biopsy however diagnostic ability clinical utility variable implementation challenging multi-gene expression biomarker panel successfully led accurate classification improve prognosis breast prostate colon cancer clinical setting however identification similar biomarkers complicated due large expression-based heterogeneity independent histology particularly solid tumour specimen contrast tissue biopsy gene expression blood non-invasive represent surrogate measurement tissue-specific gene expression potentially also aid disease prediction specifically gene expression profiling whole blood specimen separated blood cell cell-free rna blood patient suggests development progression detected systemic alteration whole blood however whole blood gene expression study also consider expression profile specimen could influenced immune cell composition indeed elevated blood neutrophil-to-lymphocyte ratio nlr shown prognostic value patient several study close diagnosis suggesting gene expression change observed whole blood might reflect change immune cell composition whereas many study investigated gene expression difference case control blood specimen sampled diagnosis investigation pre-diagnostic blood specimen rare consequently unclear whether diagnostic whole blood gene expression marker predictive pre-diagnostic blood specimen work used genome-wide expression data three study one diagnosis two prospective study identified candidate marker using whole blood specimen taken diagnosis confirmed case compared individual suspected confirmed negative evaluation resembles screening situation evaluated case–control difference trend time specimen collection diagnosis candidate marker two prospective study method study sample analysis work based whole blood specimen questionnaire registry-based data three different study one diagnostic hospital-based study norwegian lung cancer biobank nlcb two prospective population-based study norwegian woman cancer study nowac trøndelag health study hunt3 diagnostic study includes blood specimen collected detailed clinical evaluation lung cancer comprises individual confirmed positive diagnosis case individual underwent diagnostic workup suspicion confirmed suspected case suspicion mainly based finding imaging mainly scan suspected case included control group work considered false positive hereafter referred falsepos scenario resembles realistic screening situation compared inclusion healthy individual prospective study blood specimen collected prior diagnosis case specimen matching individual never diagnosed cancer control included study identified using linkage national cancer registry norway case included specimen taken eight year prior diagnosis matching criterion case control slightly differed two prospective study supplementary method study histological subtypes considered non-small cell nsclc including adenocarcinoma squamous cell carcinoma group nsclcs small cell sclc definition case three study patient defined person registered international classification disease icd-10 topography code c33–c34 classified case early- middle- late-stage based information medical journal data nlcb study tnm status national cancer registry data nowac hunt3 study classification registry see supplementary table aim construct staging information could harmonized across cohort describe early-stage case group local disease middle-stage case group regional disease regional spread late-stage case group advanced systemic disease spread whole body candidate gene identification diagnostic study whole analysis workflow visualized supplementary fig rna-seq data diagnostic study nlcb generated processed described supplementary method differentially expressed gene identified using bioconductor package limma v3.46.0 combined voom transformation expressed gene represented log read per million rpm value limma model contrast defined stage histological subtype information model used identify candidate gene included case status case falsepos stage status early- middle- late-stage histological subtype nsclcs sclc smoking status never/ever age scaled sex addition technical variation supplementary fig -values false discovery rate fdr -adjusted using benjamini–hochberg method included several subcomparisons identify gene case versus falsepos versus iii versus nsclc versus nsclc sclc versus nsclc late-stage case versus falsepos vii nsclc versus falsepos viii early-stage versus late-stage case identified significantly gene subcomparisons investigated using pathway enrichment analysis package reactomepa v1.34.0 top five ten enriched pathway up- downregulated gene respectively visualized separate plot using dotplot function enrichplot package v1.10.2 applied stringent filtering approach filtered several lowly expressed gene high absolute log fold change value logfc expression-dependent filtering significantly gene found analysis done find robust candidate marker disease could associated also cohort specifically fitted locally estimated smoothing loess regression curve average gene expression absolute logfc significantly gene detected case–control subcomparisons used curve define stricter cut-off logfc expression-dependent filtering supplementary fig approach filtered gene low average expression high absolute logfc value found significantly analysis due heteroscedasticity rna sequencing rna-seq data compared classical filtering approach considers logfc cut-off candidate gene diagnostic study defined using following criterion absolute fold change value larger test significant gene i.e. case nsclc case late-stage case compared falsepos fdr-adjusted -value lower 0.05 iii absolute logfc value expression-dependent loess curve supplementary fig correlation expression candidate gene computed using log rpm value corrplot package v0.92 pearson correlation coefficient survival model used vital status follow-up august including cancer stage stratified early- middle- late-stage age scaled sex smoking status never/ever surv function package survival v3.2–13 -values adjusted using benjamini–hochberg correction ability candidate gene discriminate case/falsepos diagnostic study investigated using logistic regression model glm function package stats v4.0.5 receiver operating characteristic roc curve roc function package proc v1.18.0 candidate gene evaluation prospective study rna-seq microarray data prospective study nowac hunt3 generated processed described supplementary method investigated expression candidate gene prospective study focusing comparison case versus control late-stage case versus control iii nsclc case versus control identified significantly gene comparison diagnostic study data prospective study pre-processed described supplementary method analysed one combined dataset case–control comparison used logistic mixed-effects model glmer function package lme4 v1.1–28 joint analysis allowing inclusion separate study random effect individual prospective study included model adjusted age scaled sex smoking variable seven category based smoking status never/current/former pack-years see detail study random effect evaluation variation gene expression blood specimen collection diagnosis used mixed-effects model lmer function package lmertest v3.1–3 combination generalized additive model gam function package gam v1.20 lmer model included expression value candidate gene prospective case adjusted age scaled sex smoking variable addition including study random effect residual lmer model served input gam model resulting plot showed cubic regression spline time year blood sampling diagnosis case prospective study based time diagnosis plot two identified candidate gene restricted case–control comparison two gene case diagnosed within two year blood sample collection ability candidate gene discriminate case/control status prospective study investigated similarly diagnostic study smoking adjustment diagnostic prospective study smoking adjustment used model differed diagnostic nlcb prospective study nowac hunt3 smoking information patient diagnostic study could biased directly retrieved individual patient medical journal smoking information used diagnostic study therefore smoking status two category never/ever smoker considered reliable information study prospective study smoking variable seven category constructed questionnaire based smoking status never/current/former pack-years pyrs information using following criterion never smoker former smoker 10.0 pyrs former smoker 10.1–20.0 pyrs former smoker 20.1 pyrs current smoker 10.0 pyrs current smoker 10.1–20.0 pyrs current smoker 20.1 pyrs blood cell type estimate available blood count study therefore estimated blood cell type proportion blood dna methylation dnam data generated individual case falsepos diagnostic study included project using epidish algorithm non-constrained reference-based approach based robust partial correlation rpc using centdhsblooddmc.m reference matrix estimated blood cell type proportion also gene expression data rna-seq data generated nlcb study using cibersort algorithm ran cibersort using normalized non-transformed expression matrix lm22 reference file disabled quantile normalization recommended author cibersort rna-seq data logistic regression model glm function package stats v4.0.5 adjusted sex age scaled smoking status never/ever used evaluate association status blood cell type estimate prospective study estimated blood cell type proportion similarly diagnostic study using available blood dnam data dnam data available individual nowac study four individual hunt3 study control case logistic regression model glm function package stats v4.0.5 adjusted sex age scaled smoking variable seven category used evaluate association status blood cell type proportion estimated dnam rna-seq/microarray data prospective study separately included cell type estimate significantly different case falsepos diagnostic study roc curve analysis evaluate performance candidate gene discrimination case falsepos/controls diagnostic study used cell type proportion estimated blood dnam data individual remaining individual without blood dnam data available adjusted cell type proportion estimated rna-seq data using spearman rank correlation coefficient 0.8 neutrophil 0.66 cd4 cell 0.67 cell obtained using correlation cell type proportion estimate epidish versus cibersort individual available dnam gene expression data respectively supplementary fig prospective study used cell type proportion estimated blood dnam data individual nowac study four individual hunt3 study remaining four individual without blood dnam data available estimated blood cell type proportion gene expression data rna-seq data generated hunt3 study using cibersort algorithm adjusted using spearman rank correlation coefficient 0.69 neutrophil 0.63 cd4 cell 0.7 cell obtained using correlation blood cell type proportion estimated epidish versus cibersort individual dnam gene expression data available respectively ethic approval consent participate participant given written informed consent respective cohort study approved respective regional committee medical health research ethic norway rek nord 2016/175 nowac rek sør-øst 2015/78 hunt3 rek midt 2018/638 nlcb study research conducted according principle stated declaration helsinki result overview study participant study design work used whole blood specimen questionnaire registry data three different study one hospital-based diagnostic study nlcb two prospective study nowac hunt3 table see method section supplementary method description nowac included woman whereas woman nlcb hunt3 respectively analysis workflow visualized supplementary fig diagnostic study nlcb used discovery set identify candidate marker evaluated potential risk predictor two independent prospective study nowac hunt3 table main characteristic participant different study full size table identification candidate gene diagnosis generated rna-seq data whole blood specimen diagnostic study nlcb identify candidate marker comparing gene expression confirmed case confirmed negative individual falsepos rna-seq read mapped human genome reference hg38 60,675 gene filtered final count matrix 14,014 annotated gene compared gene expression different stage early- middle late-stage histological subtypes nsclc sclc using adjusted limma model considering eight different subcomparisons see method section detail detected significantly gene fdr-adjusted -value 0.05 benjamini–hochberg method following three comparison case versus falsepos fig non-small cell nsclc case versus falsepos fig late-stage case versus falsepos fig substantial difference observed late-stage case compared falsepos fig detected 2,003 1,906 3,394 gene three comparison respectively majority downregulated case up- 1,850 1,767 2,862 downregulated respectively fig a-c gene three comparison i.e. 2,003 1,906 3,394 gene investigated enriched pathway using reactome pathway analysis top two significantly fdr 0.05 upregulated pathway common three comparison neutrophil degranulation platelet activation degranulation signalling aggregation pathway many significantly downregulated pathway including rna metabolism dna replication tp53 activity fdr 0.05 fig supplementary table figure identification characteristic candidate gene diagnostic study nlcb volcano plot three case–control comparison significantly gene nsclc late-stage case versus falsepos down- upregulated gene fdr-adjusted -value fdr benjamini-hochberg method 0.05 indicated blue red respectively reactome pathway analysis upregulated downregulated gene diagnostic study top five ten significantly enriched pathway fdr 0.05 comparison included figure correlation matrix log read per million log rpm value candidate gene diagnostic study evaluated prospective study pearson correlation coefficient highly correlated candidate highlighted black line survival curve three candidate gene significant -values cox model anxa3 arg1 fdr method late-stage case 0.009 0.03 0.007 respectively high anxa3 expression also significantly related poor prognosis middle-stage case fdr 0.04 low high gene expression defined median log rpm value gene indicated low high respectively full size image applied stringent filtering approach based average gene expression absolute logfc value considering candidate gene see method section identify robust candidate disease resulted unique candidate gene supplementary table supplementary fig upregulated case compared falsepos one gene limited annotation ensg00000259753 cox model death endpoint used investigate association high versus low expression annotated candidate gene patient survival different stage group diagnostic study eight candidate gene significantly associated survival fdr 0.05 benjamini–hochberg method anxa3 arg1 haptoglobin integrin subunit alpha itga2b neuregulin nrg1 oleoyl-acp hydrolase olah late-stage hazard ratio 2.81 2.16 2.54 2.16 2.07 2.21 confidence interval 1.50–5.27 1.20–3.90 1.39–4.63 1.21–3.86 1.16–3.68 1.23–3.97 respectively anxa3 fam20a golgi associated secretory pathway pseudokinase fam20a long intergenic non-protein coding rna linc00402 middle-stage 2.48 4.17 0.26 1.11–5.54 1.72–10.12 0.10–0.64 respectively fig g-i supplementary fig evaluation candidate gene prospective study annotated candidate gene could detected gene expression datasets prospective study nowac hunt3 generated work mainly due low signal intensity microarray dataset nowac see supplementary method filtering criterion adenylate kinase ak5 arg1 anxa3 hexokinase domain containing hkdc1 indoleamine 2,3-dioxygenase ido1 itga2b integrin subunit beta itgb3 myosin light chain myl9 nrg1 olah phosphoglucomutase pgm5 pro-platelet basic protein ppbp transmembrane protein 176a tmem176a supplementary fig correlated expression value log rpm candidate gene study fig supplementary fig observed three strongly correlated cluster gene ppbp myl9 itga2b itgb3 arg1 anxa3 olah iii hkdc1 ak5 prospective study first evaluated case–control difference candidate gene observed significant association one candidate tmem176a nsclc case compared control 1.19 1.03–1.37 1.03–1.38 respectively supplementary table except tmem176a three gene anxa3 arg1 showed consistently change risk three comparison case vs. falsepos nsclc case vs. falsepos late-stage case vs. falsepos though statistically significant case versus falsepos without smoking adjustment supplementary table low effect size comparison case control surprising blood specimen case prospective study collected seemingly healthy individual year prior diagnosis gene expression change prospective case towards diagnosis would expected therefore evaluated potential trend candidate gene expression relation time specimen collection diagnosis prospective case time diagnosis model indicated trend slightly higher expression close diagnosis candidate gene arg1 noticeable two year prior diagnosis middle- late-stage case fig note trend lower arg1 expression closer time diagnosis observed early-stage case fig anxa3 showed similar trend higher expression last two year prior diagnosis arg1 supplementary fig candidate gene significant trend relation time diagnosis could observed prospective case based higher expression anxa3 arg1 close diagnosis indicated time diagnosis model restricted case–control analysis two candidate last two year prior diagnosis found significant association anxa3 arg1 three comparison nsclc late-stage case compared control supplementary table strongest association observed arg1 late-stage case 5.01 1.89–13.30 -value 1.22e-03 figure time trend arg1 expression prospective study nowac hunt3 arg1 expression early-stage middle-stage late-stage stage relation time specimen collection diagnosis time trend visualized using smoothing spline generalized additive model gam input model used residual mixed model lmer adjusted sex age scaled smoking variable addition using study random effect histological subtypes plot visualized using different point shape nsclc non-small cell sclc small cell prospective study visualized different point colour full size image blood cell type estimate one highly upregulated pathway reactome analysis neutrophil degranulation three comparison gene diagnostic study especially late-stage case fig wanted elucidate change blood cell type proportion would influence association candidate gene blood count available study estimated cell type proportion derived blood rna-seq dnam data generated individual included work unpublished dnam data see method section supplementary method detail evaluated blood cell type estimate consistently reported significantly different case falsepos proportion estimated dnam rna-seq data blood estimate cd4 cell cell neutrophil significantly associated diagnosis supplementary table prospective study blood cell type estimate obtained similarly rna-seq/microarray data dnam data individual diagnostic study see method section supplementary method detail however significant association cd4 cell cell neutrophil could observed prospective study supplementary table discrimination based candidate gene blood cell type estimate also tested ability candidate gene discriminate case controls/falsepos diagnostic study candidate gene alone able discriminate case falsepos better compared smoking status ever/never alone auc 0.63 0.57 respectively arg1 example fig including candidate gene smoking status model discriminative ability slightly improved auc 0.67 arg1 fig including blood neutrophil estimate together smoking status discriminative ability higher auc 0.72 marginally improved adding cd4 cell cell estimate model auc 0.73 discriminative ability slightly improved including candidate gene arg1 model auc 0.75 fig however significant effect discrimination observed including blood neutrophil estimate model fig supplementary fig similar observation made candidate supplementary fig figure receiver operating characteristic roc curve diagnostic prospective study arg1 candidate discrimination based case falsepos diagnostic study nlcb discrimination based case control prospective study nowac hunt3 six separate roc curve visualized model including smoking status/ variable smoking arg1 expression arg1 iii smoking status/ variable arg1 expression smoking arg1 smoking status/ variable blood neutrophil estimate smoking neu smoking status/ variable blood neutrophil cd4 cell estimate smoking neu cd4t smoking status/ variable blood neutrophil cd4 cell cell estimate candidate gene expression smoking neu cd4t arg1 roc curve smoking status/ variable blood neutrophil cd4 cell cell estimate smoking neu cd4t shown similar smoking neu cd4t roc curve almost identical auc value diagnostic study smoking status defined never/ever smoker prospective study smoking variable seven category combining smoking status never/current/former pack-years see method section detail full size image prospective study discriminative ability candidate gene alone lower smoking variable seven category alone auc 0.59 0.75 respectively arg1 example fig discrimination improved marginally candidate gene smoking variable included model auc 0.76 arg1 fig remained additionally including neutrophil cd4 cell cell blood estimate candidate gene arg1 model auc 0.76 fig roc curve auc value similar arg1 tmem176a nrg1 auc 0.59 anxa3 auc 0.58 lower candidate gene prospective study supplementary fig overall blood cell type estimate candidate gene improved discrimination diagnostic study compared smoking status information never/ever alone fig supplementary fig however prospective study discriminative ability candidate gene improve beyond smoking variable information adding blood cell type estimate supplementary fig discussion aimed identify candidate gene associated whole blood specimen taken diagnosis using genome-wide expression profiling evaluate association two prospective study case–control comparison filtering identified candidate gene diagnostic study high expression three candidate gene anxa3 arg1 found strongly associated survival late-stage case diagnostic study fdr value 0.009 0.03 0.007 respectively prospective study one candidate tmem176a showed significant though weak 1.19 association case–control comparison prospective nsclc case whole blood specimen eight year prior diagnosis however high expression two candidate anxa3 arg1 strongly associated especially late-stage last two year prior diagnosis 3.47 5.00 respectively diagnostic study observed significant gene expression difference late-stage nsclc case compared control falsepos predominantly enriched pathway neutrophil degranulation upregulated case differential gene expression study whole blood typically confounded cell type composition change investigated blood cell type estimate based either blood dna methylation gene expression data associated expected blood neutrophil estimate together cd4 cell cell estimate significantly associated diagnosis supporting earlier study elevated neutrophil-to-lymphocyte ratio prognostic value potentially month prior diagnosis observation primarily driven neutrophil including blood cell type estimate especially blood neutrophil together candidate gene roc curve analysis strongly improved discriminative ability diagnosis compared smoking status alone higher expression anxa3 arg1 significantly associated lower survival among late-stage case association last two year prior diagnosis novel however two gene considerably improve discriminative ability prospective case beyond smoking information available work overexpression anxa3 previously linked tumour proliferation metastasis many tumour including anxa3 reported diagnostic prognostic potential several cancer including study small number participant performed far work high anxa3 expression associated lower survival late-stage case agreement previous work however association anxa3 expression remains controversial up- downregulation tissue observed although high blood anxa3 expression associated different cancer type interestingly anxa3 included blood-based 7-gene biomarker panel colorectal cancer discrimination work appears first one reporting high anxa3 expression whole blood patient high level arg1 associated cell cycle arrest functional unresponsiveness cell high arg1 expression observed infection including severe covid-19 patient many human cancer tumour tissue peripheral blood including high arg1 expression seems negative predictive factor many cancer correlate aggressive phenotype line report observed trend higher arg1 expression last two year prior diagnosis late-stage cancer case however high amount intratumoural arg1 neutrophil might always associated worse cancer prognosis appears combining arg1 -targeting vaccine anti-pd-1 immunotherapy increase cell infiltration tumour nct03689192 interestingly large ongoing clinical trial arginase inhibitor incb001158 single agent combination immunotherapy patient advanced metastatic solid tumour nct02903914 note observed trend lower arg1 expression towards diagnosis early-stage case although interesting observation need followed-up work since dataset included early-stage case upregulation arg1 anxa3 previously observed several disease likely specific higher expression could rather associated disease severity still known whether association represent signal linked disease development systemic response disease tmem176a two relevant candidate gene associated work tmem176a expression overall significantly fdr 0.05 associated prospective case though weakly 1.19 although upregulation tmem176a previously observed nsclc tissue might act tumour suppressor gene colorectal esophageal cancer tissue aware reported association peripheral blood expression significantly associated survival late-stage case diagnostic study work agreement previous study based peripheral blood tissue specimen higher serum haptoglobin protein level also previously associated advanced poor prognosis nsclc patient association candidate gene change considerably adjustment smoking suggesting marker unrelated tobacco exposure addition none candidate gene previously found associated smoking interestingly compared similar gene expression study candidate marker found study anxa3 arg1 observed significantly upregulated fdr 1.55e-04 lung cancer subtype defined lc2 compared healthy control study performed zhang colleague logfc value 0.69 0.79 1.38 respectively addition four candidate gene ak5 ido1 nrg1 olah also found study except ido1 effect direction observed two candidate marker anxa3 arg1 significantly upregulated fdr 4.82e-02 nsclc case compared control training set dataset study performed zander colleague logfc value 0.70 1.09 respectively adjusted age scaled sex individual ever smoker additionally except one hkdc1 candidate gene detected effect direction nsclc case compared control study 0.002 binomial test several screening trial conducted progress length screening interval discussed tested biennial screening round high-risk individual suggested promising strategy avoiding high percentage interval cancer reducing unnecessary radiation exposure screening potentially complemented blood biomarker panel improve overall screening performance personalized strategy documented pastorino colleague present result support systemic gene expression change indicating cancer progression may detected whole blood already prior diagnosis main strength work lie combining diagnostic study exploratory analysis leading identification candidate evaluated two prospective study unique approach identification potential cancer candidate marker approach could also evaluate expression trend candidate gene individual prior diagnosis addition diagnostic study included symptomatic individual falsepos instead healthy control resembles screening situation included subtypes stage work work limitation addressed future study although initially identified unique candidate gene diagnostic study based rna-seq analysis one gene excluded due limited annotation gene excluded low signal intensity microarray dataset nowac study majority prospective specimen work nowac study however gene could potentially relevant gene associated future study ideally use rna-seq instead microarrays genome-wide expression analysis addition expression difference prospective study could affected different sampling system blood specimen nowac hunt3 study collected using paxgene tempus tube respectively smoking information diagnostic study found reliable beyond smoking status contrast detailed smoking information available prospective study therefore adjusting detailed information smoking habit could resulted residual confounding smoking diagnostic study analysis potentially also explain observe better discriminative ability candidate gene marker roc curve analysis diagnostic study compared prospective study addition time diagnosis analysis prospective study performed different individual different time diagnosis longitudinal analysis individual could performed since whole blood specimen included individual available multiple time point prior diagnosis summary identified candidate gene whole blood specimen using diagnostic prospective study high expression several candidate gene strongly associated lower survival diagnostic study strongest association observed anxa3 arg1 prospective late-stage case especially within two year diagnosis blood cell type estimate cd4 cell cell especially neutrophil strongly associated diagnostic study improved discriminative ability diagnosis beyond inclusion candidate gene conclusion result indicate increased expression anxa3 arg1 detected whole blood specimen close diagnosis beyond lc-associated change blood cell type proportion gene represent diagnostic prognostic marker late-stage